Connect Biopharma's rademikibart hits primary endpoint in Phase 2 COPD trial, cutting treatment failure 81% at 28 days

Connect Biopharma reported positive preliminary topline data from its global Phase 2 study of rademikibart in adults with COPD and type 2 inflammation, with an 81% reduction in treatment failure at 28 days (p=0.012, n=159). Rademikibart targets the same pathway as Dupixent, approved for chronic COPD.

Detected & updated continuously · Source: Nebula